Investigator: Professor Mario Alvarez-Jimenez
What is Rebound?
Rebound is a new digital platform created by Orygen Digital for young people who have experienced a major depressive disorder.
- guided therapeutic journeys, tailored for each user;
- a personal toolkit of proven strategies that people can access anytime, anywhere;
- a safe and inspiring social network to connect with others and troubleshoot problems; and
- a support team of online therapists, peer workers and career consultants.
The platform was co-designed with young people who have experience of mental illness and has been successfully pilot tested.
What is the Rebound study testing?
The Rebound Study is testing whether Rebound helps prevent relapse of major depression in young people.
The Rebound study is a randomised controlled research project. There will be two groups in the study. One group will use the Rebound platform and one group will use an alternate website. The results will then be compared to see if one treatment is better. During the study people in both groups will still have access to all the usual treatments available to them.
What does the study involve?
Study participants will complete an initial screening assessment to determine whether they are eligible for the study.
If this initial assessment indicates the participant is eligible for the Rebound study, they will then complete a baseline assessment. The screening and baseline assessments will take approximately two hours but can be done over two sessions via telehealth.
Participants will then be allocated to a group. Both groups will be monitored for 18 months with brief monthly assessments and longer assessments (similar to the screening/baseline assessment) at six, twelve and 18 months.
Participants will be reimbursed for time taken to attend appointments ($30 per hour, up to two hours).
Young people aged 14–27 who have experienced a major depressive disorder are eligible to participate in this study.
Young people or their carers can contact the study team directly, or they can be referred to the study by their GP or mental health clinician or service.
If you would like to talk to someone about the study, please contact the study coordinator, Daniela, on 0408 607 919 or [email protected]
SEP v1310322 HREC/42967/MH-2018